Bank of America upgraded UnitedHealth to Buy from Neutral, raising its target to $450 from $420, while Morgan Stanley lifted its to $453 and Truist to $440, driving shares up over 5% on June 4. Analysts cited improving medical cost trends and near-term data supporting a favorable Q2 setup.
Bank of America upgraded UnitedHealth to Buy from Neutral, raising its price target to $450 from $420. Morgan Stanley lifted its target to $453 and Truist increased theirs to $440, driving the stock up more than 5% on June 4.
Analysts pointed to favorable first-quarter medical cost trends, noting that softer utilization from weak flu activity and storms may have benefited profits but incoming April and May data suggest sustained moderation in medical costs, enhancing the company's risk-reward profile ahead of Q2 earnings.
Emerging AI-driven efficiencies in care management could deliver roughly 45% average EPS upside as technologies scale. Analysts expect these tailwinds, combined with ongoing margin recovery in government and commercial segments, to support a strong second-quarter report and potentially lift broader managed care sentiment.
Finance
